drugset / Trial / NCT01133626

Hypothalamic-Pituitary-Adrenal (HPA) Axis Study in Adult and Adolescent Subjects With Perennial Allergic Rhinitis (PAR)

NCT01133626

Phase 3 Completed 107 enrolled Teva Branded Pharmaceutical Products R&D, Inc.
RandomizedParallel-groupTriple-blindTreatment

Summary

The purpose of the study is to evaluate the effects of BDP HFA Nasal Aerosol on HPA-axis function.

Timeline

Start
2010-06
Primary completion
2010-09
Completion
2010-09

Publications

Drugs

EvaluationDrugModalityDoseRoute
Comparator Prednisone Other / unclassified 10 mg
Subject beclomethasone dipropionate Other / unclassified 320 ug Intranasal